Astrana Health (ASTH) has wrapped up FY 2025 with fourth quarter revenue of US$950.5 million and basic EPS of US$0.12, alongside trailing 12 month revenue of about US$3.2 billion and EPS of US$0.46. This gives investors a clear read on both the latest quarter and the full year run rate. Over recent periods the company has seen quarterly revenue move from US$478.7 million in Q3 2024 to US$665.2 million in Q4 2024 and then into the US$620.4 million to US$956.0 million range through FY 2025, while basic EPS has ranged from a loss of US$0.15 in Q4 2024 to US$0.19 in Q2 2025. With earnings forecasts pointing to strong growth and margins currently sitting at relatively thin levels, this result puts the quality and sustainability of profitability firmly in focus for investors.

See our full analysis for Astrana Health.

With the latest numbers on the table, the next step is to see how this earnings profile lines up against the big narratives around Astrana Health, from growth potential to financial risk.

TTM earnings of US$22.5m on US$3.2b revenue keep margins thin

• Over the last twelve months, Astrana Health generated about US$3.2b in revenue and US$22.5m in net income, which works out to a net margin of 0.7% compared with 2.1% a year earlier.
• Consensus narrative sees full risk contracts and acquisitions supporting more durable profit growth over time, yet the current 0.7% margin means the business is still running on a tight spread.
  • With trailing 12 month EPS at US$0.46 and analysts expecting earnings growth of about 30.35% per year, the story of future margin expansion is being built on a low profitability base today.
  • Revenue forecasts of about 10.8% per year alongside that higher earnings growth expectation imply a bigger role for cost control and efficiency than for top line acceleration in that balanced view.

High 79.4x P/E versus 22.4x industry challenges bearish worries

• The stock trades on a trailing P/E of 79.4x compared with 22.4x for the US Healthcare industry and 27.3x for peers, while DCF fair value in this dataset is US$123.28 against a current share price of US$36.08.
• Bears point to rich valuation multiples and weaker five year earnings trends, yet the gap between the current price and both DCF fair value and the analyst price target of about US$36.89 raises questions about how far the bearish case can stretch.
  • Trailing earnings declined at about 11.5% per year over five years and include a one off loss of US$16.1m, which critics highlight when arguing that the 79.4x P/E leaves little room for earnings missteps.
  • At the same time, a current share price of US$36.08 that sits about 70.7% below the DCF fair value and slightly below the US$36.89 analyst target means some of that concern already appears reflected in the market valuation.

Skeptics often focus on headline valuation, but the detailed bear case leans heavily on margin and policy risks that you can weigh directly against the latest numbers in the full narrative. 🐻 Astrana Health Bear Case

Quarterly EPS swings test bullish confidence in margin expansion

• Across FY 2025, quarterly basic EPS moved from US$0.14 in Q1 to US$0.19 in Q2, US$0.01 in Q3 and US$0.12 in Q4, while quarterly net income ranged between US$0.4m and US$9.4m on revenue between US$620.4m and US$956.0m.
• Bulls argue that full risk contracts and integration benefits can support much higher earnings, yet the recent EPS volatility and thin net income figures highlight how much execution is needed for that story to play out.
  • Analysts in the bullish camp are working from current margins around 0.7% and EPS of US$0.46 when they project earnings to rise to more than US$100m over time, so the quarterly pattern of EPS near zero in Q3 and modest in Q4 is an important reality check.
  • The move from a loss of US$6.9m in Q4 2024 to a profit of about US$6.0m in Q4 2025 shows that profitability can shift quickly across periods, which is a key consideration for any view that expects steady margin expansion from here.

Supporters of the bullish view see those earnings swings as growing pains, not a ceiling, and the full bull narrative lays out how contract mix and integration could reshape that EPS profile over time. 🐂 Astrana Health Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Astrana Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of thin margins and rich valuation leaves you uncertain, now is a good time to review the full picture yourself and weigh both the concerns and the potential upside using our 2 key rewards and 3 important warning signs

See What Else Is Out There

Astrana Health is working with thin 0.7% margins, volatile quarterly EPS and a rich 79.4x P/E that leaves little room for earnings disappointment.

If those tight margins and premium valuation make you cautious, it can be useful to compare with companies screened for stronger fundamentals and pricing support through the 51 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.